Your browser doesn't support javascript.
loading
Rapid In-Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Using Povidone-Iodine Oral Antiseptic Rinse.
Bidra, Avinash S; Pelletier, Jesse S; Westover, Jonna B; Frank, Samantha; Brown, Seth M; Tessema, Belachew.
Afiliação
  • Bidra AS; Department of Reconstructive Sciences, University of Connecticut Health Center, Farmington, CT.
  • Pelletier JS; Ocean Ophthalmology Group, Miami, FL.
  • Westover JB; The Institute for Antiviral Research at Utah State University, Logan, UT.
  • Frank S; Department of Otolaryngology, University of Connecticut Health Center, Farmington, CT.
  • Brown SM; Department of Otolaryngology, University of Connecticut Health Center, Farmington, CT.
  • Tessema B; ProHealth Physicians Ear, Nose and Throat, Farmington, CT.
J Prosthodont ; 29(6): 529-533, 2020 Jul.
Article em En | MEDLINE | ID: mdl-32511851
ABSTRACT

PURPOSE:

To investigate the optimal contact time and concentration for viricidal activity of oral preparation of povidone-iodine (PVP-I) against SARS-CoV-2 ('corona virus') to mitigate the risk and transmission of the virus in the dental practice. MATERIALS AND

METHODS:

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) USA-WA1/2020 strain, virus stock was tested against oral antiseptic solutions consisting of aqueous povidone-iodine (PVP-I) as the sole active ingredient. The PVP-I was tested at diluted concentrations of 0.5%, 1%, and 1.5%. Test media without any virus was added to 2 tubes of the compounds to serve as toxicity and neutralization controls. Ethanol (70%) was tested in parallel as a positive control, and water only as a negative control. The test solutions and virus were incubated at room temperature (22 ± 2 °C) for time periods of 15 and 30 seconds. The solution was then neutralized by a 1/10 dilution in minimum essential medium (MEM) 2% fetal bovine serum (FBS), 50 µg/mL gentamicin. Surviving virus from each sample was quantified by standard end-point dilution assay and the log reduction value (LRV) of each compound compared to the negative (water) control was calculated.

RESULTS:

PVP-I oral antiseptics at all tested concentrations of 0.5%, 1%, and 1.5%, completely inactivated SARS-CoV-2 within 15 seconds of contact. The 70% ethanol control group was unable to completely inactivate SARS-CoV-2 after 15 seconds of contact, but was able to inactivate the virus at 30 seconds of contact.

CONCLUSIONS:

PVP-I oral antiseptic preparations rapidly inactivated SARS-CoV-2 virus in vitro. The viricidal activity was present at the lowest concentration of 0.5 % PVP-I and at the lowest contact time of 15 seconds. This important finding can justify the use of preprocedural oral rinsing with PVP-I (for patients and health care providers) may be useful as an adjunct to personal protective equipment, for dental and surgical specialties during the COVID-19 pandemic.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia Viral / Infecções por Coronavirus / Pandemias / Anti-Infecciosos Locais Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia Viral / Infecções por Coronavirus / Pandemias / Anti-Infecciosos Locais Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article